Urinary Antiseptics, Drugs used in STDs and UTIANUSHA SHAJI
The current presentation includes the pharmacology of urinary antiseptics, Drugs used in STDs and UTI.
Reference: Essentials of Medical Pharmacology, K D Tripathi, Seventh Edition
Urinary Antiseptics, Drugs used in STDs and UTIANUSHA SHAJI
The current presentation includes the pharmacology of urinary antiseptics, Drugs used in STDs and UTI.
Reference: Essentials of Medical Pharmacology, K D Tripathi, Seventh Edition
Basic principles of chemotherapy,The Development of Chemotherapy,Molecular basis of chemotherapy ,Biochemical reaction as potent targets,Antimicrobial Drugs,Mechanisms of action of Antibacterial Drugs,Aminoglycosides,Macrolides,Tetracyclines,Chloramphenicol,Sulphonamides,Antibacterials – Competitive Inhibitors,Quinolones (GABA antagonists),Antiviral Drugs,Drugs that Inhibit Nucleic Acid Synthesis
Nucleoside and Nucleotide Analogs
aminoglycosides, antibacterials – competitive inhibitors, antimicrobial drugs, antiviral drugs, basic principles of chemotherapy, biochemical reaction as potent targets, chloramphenicol, drugs that inhibit nucleic acid synthesis
nucleosi, macrolides, mechanisms of action of antibacterial drugs, molecular basis of chemotherapy, quinolones (gaba antagonists), sulphonamides, tetracyclines, the development of chemotherapy,
This PPT covers Drug therapy for Viral Infection or disease. It includes Viral replication cycle, classification of antiviral drugs, Anti-Herpes drug, Anti Influenza drugs, Anti hepatitis drugs and anti retroviral drugs
Basic principles of chemotherapy,The Development of Chemotherapy,Molecular basis of chemotherapy ,Biochemical reaction as potent targets,Antimicrobial Drugs,Mechanisms of action of Antibacterial Drugs,Aminoglycosides,Macrolides,Tetracyclines,Chloramphenicol,Sulphonamides,Antibacterials – Competitive Inhibitors,Quinolones (GABA antagonists),Antiviral Drugs,Drugs that Inhibit Nucleic Acid Synthesis
Nucleoside and Nucleotide Analogs
aminoglycosides, antibacterials – competitive inhibitors, antimicrobial drugs, antiviral drugs, basic principles of chemotherapy, biochemical reaction as potent targets, chloramphenicol, drugs that inhibit nucleic acid synthesis
nucleosi, macrolides, mechanisms of action of antibacterial drugs, molecular basis of chemotherapy, quinolones (gaba antagonists), sulphonamides, tetracyclines, the development of chemotherapy,
This PPT covers Drug therapy for Viral Infection or disease. It includes Viral replication cycle, classification of antiviral drugs, Anti-Herpes drug, Anti Influenza drugs, Anti hepatitis drugs and anti retroviral drugs
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
2. INTRODUCTION
• Tuberculosis (TB) is an infectious disease usually caused by
Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally
affects the lungs, but can also affect other parts of the body.
5. MECHANISM OF ACTION
• First –Line Drugs:
• These drugs are used in combinations of two or more agents until bacterial
conversation occurs or maximum improvement is seen.
• The First-line drugs for treating tuberculosis are as follows:
• Isoniazid [INH] (Nydrazid), which affects the mycolic acid coating of the
bacterium.
• Rifampin (Rifadin, RImactane), which alters DNA and RNA activity in the
bacterium.
• Ethionamide (Trecator SC), which prevents cell division.
• Rifapentine (Priftin), which alters DNA and RNA activity, causing cell death.
6. • Second-line drugs :
• If the patient cannot take one or more of the first-line drugs, or if the disease
continues to progress because of the emergences of a resistance strain, the
line drugs can be used.
• These drugs are used in combination with at least one other antituberculosis
The Second-line drugs for treating tuberculosis are as follows:
• Ethambutol (Myambutol), which inhibits cellular metabolism.
• Pyrazinamide (generic), which is both bactericidal and bacteriostatic.
7. • Third-line drugs:
• If therapeutic success is still not achieved, a third- line combination of two
antituberculosis drugs can be tried.
• Using the drug in combination helps to decrease the emergence of resistant
strains and to affect the bacteria at various phases during their long and slow life
cycle.
• The Third-line drugs for treating tuberculosis are as follows:
• Capreomycin (Capastat), whose mechanism of action is not known.
• Cycloserine (Seromycin), which inhibits cell wall synthesis and leads to cell death.
11. NURSES RESPONSIBILITY
• Educate the patient and family regarding the disease, its prevention and
treatment.
• Check culture and sensitivity reports to ensure that this is the drug of choice for
this patient and arrange repeated cultures if response is not as anticipated.
• Monitor renal and liver function test results before and periodically during
therapy to arrange for dosage reduction as needed.
• Ensure that the patient receives the full course of the drugs to improve
effectiveness and decrease the risk of development of resistant bacterial strains.
